Logo

Caliper Shares Pull Back in Advance of Q2 Results

Aug 04, 2008
NEW YORK (GenomeWeb News) – Shares of Caliper Life Sciences closed down more than 12 percent in Monday trade on the Nasdaq in advance of the release of its second-quarter results on Wednesday.
 
As reported Friday by GenomeWeb Daily News, Caliper’s stock had gained around 53 percent in the month of July, after it had declined steadily through the first half of the year.
 
The Hopkinton, Mass.-based manufacturer of in vivo and in vitro cell imaging systems is scheduled to release its second-quarter earnings report on Wednesday. Analysts estimate, on average, the Caliper will report revenues of $35.2 million and a loss per share of $.03.
 
Caliper’s shares finished the trading session Monday down 12.2 percent at $3.68.
Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.